Infectious Diseases Point Of Care Diagnostics Market projected to grow with significant CAGR over th
Posted: May 07, 2018
Point of care diagnostics refers to the tests carried at a site of the patient care to provide immediate results. These diagnostics improve the disease management and detection. Infectious diseases are caused by various microorganisms such as virus, bacteria, fungi, and parasites. It reduces the time between disease testing and diagnosis of an infection. Nowadays most of the infectious diseases such as HIV, tuberculosis, influenza, tropical diseases, and sexually transmitted infections are diagnosed by the point of care testing. The major advantages with the point of care testing are a reduction of diagnosis time, postoperative care time, improvement in disease outcomes, accuracy in results, and simple methods for diagnosis of the infectious diseases.
The factors such as increase in the incidence and prevalence of infectious diseases such as malaria, dengue, HIV, rise in healthcare expenditure, growing investments from public and private sectors for the development of new products, rising government support towards the adoption of point of care devices are expected to boost global infectious disease point of care diagnostics market. Moreover, the technological advancements in point of care diagnostic devices and introduction of home-based point of care devices are also anticipated to boost the infectious disease point of care diagnostics market. However, reluctance among the patients to change in existing diagnostic practices, strict regulatory policies, and reimbursement issues might hold the growth of global infectious disease point of care diagnostics market.
A sample of this report is available upon request @
The infectious disease point of care diagnostics market is categorized as-
1. Product type
- Infectious Disease Testing Kits & Reagents
- HIV Infection
- Respiratory Infections
- Sexually-Transmitted Diseases (STDs)
- Hematology Testing Kits
- Urinalysis Testing Kits
2. Type of disease
- Bacterial Infections
- Fungal Infections
- Viral Infections
- Cardiovascular Infections
- GI Infections
- Sexually Transmitted Disease
- CNS Infections
3. Prescription mode
- Over-The-Counter (OTC) Testing Kits
- Prescription-based Testing Kits
To view TOC of this report is available upon request @
Professional diagnostic centers such as hospitals and outpatient healthcare setting, homecare, etc.
And lastly, geographically the global infectious disease point of care diagnostics market has been divided into following regions- North America, Latin America, Europe, Middle East & Africa and Asia-Pacific. North-America holds the largest share in global infectious disease point of care diagnostics market due to the dominance of infectious diseases especially in the U.S. The European region is the second largest market due to improved healthcare infrastructure, an increase in the prevalence of bacterial and viral diseases. Moreover, Asia-Pacific region has been growing in infectious disease point of care diagnostics market owing to the high prevalence of infectious diseases, unhygienic environment, and huge investment opportunities due to increasing healthcare expenditure. Factors such as the launch of new products, approvals from various regulatory bodies, acquisitions and mergers, partnerships, collaborations, and joint ventures are will boost the growth of global infectious disease point of care diagnostics market. For instance, in 2015, FDA had approved Alere for its first CLIA waiver for the nucleic acid-based test, Influenza A&B. Further Roche’s CLIA waiver for Cobas Liat System and Strep A.
Need more information about this report @
Some of the key players in the global infectious disease point of care diagnostics market are Cepheid Inc. (Danaher Corporation) (U.S.), Abbott Laboratories, Inc. (U.S.), F. Hoffmann La Roche Limited (Switzerland), Beckman Coulter, Inc. (U.S.), Siemens AG (Germany), Johnson & Johnson Services, Inc. (U.S.), Instrumentation Laboratory (U.S.), Becton, Dickinson and Company (U.S.), Alere Inc. (U.S.), Nova Biomedical (U.S.), Thermo Fisher Scientific Inc. (U.S.), and Quidel Corporation (U.S.) to name a few. In 2014, Spartan Biosciences had been approved for Spartan RX CYP2C19 system from Health Care Canada for its genetic testing. Similarly, Roche bought point of care molecular testing company iQuum for $275 million.
Get access to full summary @
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Contact to Precision Business Insights,
152 – 160 City Road,
London EC1V 2NX
Website @ https://www.precisionbusinessinsights.com